Mga Batayang Estadistika
| CIK | 1771910 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ADC Therapeutics SA
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
Filing Fee Table (filed herewith) Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 ADC Therapeutics SA Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Shares, par value CHF 0. |
|
| August 12, 2025 |
Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shar |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2025 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number |
|
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025 As filed with the Securities and Exchange Commission on August 12, 2025 Registration No. |
|
| July 10, 2025 |
ADC THERAPEUTICS SA 27,726,052 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-288437 PROSPECTUS ADC THERAPEUTICS SA 27,726,052 Common Shares Pursuant to this prospectus, the selling shareholders may offer an aggregate of 27,726,052 common shares from time to time if and to the extent as they may determine as described in the section entitled “Plan of Distribution” at prevailing market prices, at prices different than pre |
|
| July 7, 2025 |
July 7, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Shares 457(c) 27,726,052 (2) $2. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025. As filed with the Securities and Exchange Commission on June 30, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R. |
|
| June 12, 2025 |
Form of securities purchase agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 11, 2025, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland (the “Company”), and the undersigned investor (the “Investor”). Substantially concurrently with the execution of this Agre |
|
| June 12, 2025 |
Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO A REGISTRATION STATEMENT RELATED THERETO THAT IS IN EFFECT UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITI |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2025 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| June 5, 2025 |
Articles of Association of ADC Therapeutics SA Exhibit 3.1 Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorpora |
|
| June 5, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2025 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N |
|
| May 14, 2025 |
Exhibit 99.1 ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty pati |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2025 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 21, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 9, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 27, 2025 |
Exhibit 99.1 ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2025 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| March 27, 2025 |
Insider Trading Policy EXHIBIT 19.1 Effective January 1, 2024 ADC Therapeutics Insider Trading Policy 1 Insider Trading Policy Table of Contents 1. Applicability 4 2. General Policy: No Trading or Tipping While in Possession of Material Non-Public Information 4 3. Definitions 4 4. Trading Prohibitions During “Blackout Periods” 6 5. Additional Trading Restrictions for Company Insiders 7 6. Post-Ter |
|
| March 27, 2025 |
Rule 10b5-1 Plan Policy EXHIBIT 19.2 Effective January 1, 2024 ADC Therapeutics Rule 10b5-1 Plan Policy 1 Rule 10b5-1 Plan Policy Table of Contents 1 1 2 1 Purpose 3 2 Eligible Persons 3 3 Pre-Clearance and Pre-Approval Requirements 3 4 3 5 Prescribed Requirements for Trading Plans 3 5.1 Adoption Date 3 5.2 Specifications 3 5.3 Duration 4 5.4 Commencement of Transactions 4 5.5 Suspensions 4 5.6 Re |
|
| March 27, 2025 |
EXHIBIT 4.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION The Company We are a Swiss stock corporation (société anonyme) organized under the laws of Switzerland. We were incorporated as a Swiss limited liability company (société à responsabilité limitée) on June 6, 2011 with our registered office and domicile in Epalinges, Canton of Vaud, Switzerland. We converted to a Swiss stock corpo |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| March 27, 2025 |
Exhibit 21.1 Subsidiaries of ADC Therapeutics SA Name of Subsidiary Jurisdiction of Organization ADC Therapeutics America, Inc. United States ADC Therapeutics (UK) Limited England |
|
| March 27, 2025 |
Articles of Association of ADC Therapeutics SA EXHIBIT 3.1 Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorpora |
|
| February 14, 2025 |
EX-99.A 2 ss4361444ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G, dated December 31, 2024 (this “Schedule 13G”), with respect to the Common Shares, par value CHF 0.08 per share, of ADC Therapeutics SA is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Secu |
|
| January 13, 2025 |
JPMorgan 43 rd Annual Healthcare Conference January 2025 Exhibit 99.1 JPMorgan 43 rd Annual Healthcare Conference January 2025 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or rep |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Numbe |
|
| November 14, 2024 |
ADCT / ADC Therapeutics SA / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427858d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ADC Therapeutics SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 14, 2024 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ADC Therapeutics SA, which may be deemed necessary |
|
| November 13, 2024 |
ADCT / ADC Therapeutics SA / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d882324dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ADC THERAPEUTICS SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 13, 2024 |
Articles of Association of ADC Therapeutics SA Exhibit 3.1 Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorpora |
|
| November 13, 2024 |
ADCT / ADC Therapeutics SA / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d897440dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ADC THERAPEUTICS SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 13, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 11, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Numb |
|
| November 7, 2024 |
Exhibit 99.1 ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th annual American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 pro |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Numbe |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 9, 2024 |
August 9, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024. As filed with the Securities and Exchange Commission on August 6, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R |
|
| August 6, 2024 |
Second Limited Waiver to Loan Agreement and Guarant EXHIBIT 10.1 Execution Version US-DOCS\151619295.4 SECOND LIMITED WAIVER TO LOAN AGREEMENT AND GUARANTY THIS SECOND LIMITED WAIVER TO LOAN AGREEMENT AND GUARANTY (this “Waiver”) is entered into effective as of June 24, 2024 (the “Effective Date”) among ADC THERAPEUTICS SA, a company formed under the laws of Switzerland (the “Borrower”), each of the Borrower’s Subsidiaries party hereto, the Lenders |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| August 6, 2024 |
Open Market Sale AgreementSM, dated August 6, 2024, between ADC Therapeutics SA and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM August 6, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ADC Therapeutics SA, a Swiss stock corporation (société anonyme) domiciled in Epalinges, Switzerland, and organized under the laws of Switzerland (the “Company”), proposes, subject to the terms and conditions stated herein, to sell from time to time through Jeffer |
|
| August 6, 2024 |
EX-99.1 2 adct-20240630pressrelease.htm EX-99.1 Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all p |
|
| June 14, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| June 14, 2024 |
Articles of Association of ADC Therapeutics SA Exhibit 3.1 Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorpora |
|
| May 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N |
|
| May 14, 2024 |
Corporate Presentation 2Q 2024 Exhibit 99.1 Corporate Presentation 2Q 2024 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the present |
|
| May 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/ |
|
| May 8, 2024 |
Exhibit 1.1 ADC Therapeutics SA 13,411,912 Common SHares, nominal Value CHF 0.08 PER SHARE Pre-funded warrants to purchase 8,163,265 common sHARES, nominal Value CHF 0.08 PER SHARE UNDERWRITING AGREEMENT May 6, 2024 May 6, 2024 Jefferies LLC Guggenheim Securities, LLC Cantor Fitzgerald & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Jefferies LLC 520 Madison Ave |
|
| May 8, 2024 |
Exhibit 4.1 WARRANT TO PURCHASE COMMON SHARES OF ADC THERAPEUTICS SA No. W-PF-[#] May 8, 2024 The undersigned, ADC Therapeutics SA, a Swiss stock corporation (société anonyme) organized under the laws of Switzerland (together with its successors and assigns, the “Company”), hereby grants to [warrant holder name], subject to the terms and conditions herein, the right to subscribe for and purchase, |
|
| May 7, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-270570 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED MARCH 14, 2024) ADC THERAPEUTICS SA 13,411,912 Common Shares Pre-Funded Warrants to Purchase 8,163,265 Common Shares We are offering (i) 13,411,912 of our common shares and (ii) pre-funded warrants to purchase 8,163,265 of our common shares (collectively, the “securities”). The pre-funded w |
|
| May 6, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-270570 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where such offer or sale is not permitted. Subject to Co |
|
| May 6, 2024 |
Exhibit 99.1 ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL Initial MZL IIT Phase |
|
| May 6, 2024 |
mzlpresentation5624 May 2024 ZYNLONTA R/R MZL Phase 2 IIT Initial Data Exhibit 99. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/ |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 3, 2024 |
ADCT / ADC Therapeutics SA / Oaktree Capital Group Holdings GP, LLC - SC 13G Passive Investment SC 13G 1 ef20028420sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ADC Therapeutics SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) April 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate th |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 25, 2024 |
ADCT / ADC Therapeutics SA / AUVEN THERAPEUTICS HOLDINGS LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title and Class of Securities) H0036K147 (CUSIP Number) Stephen Evans-Freke Auven Therapeutics Holdings L.P. 171 Main Street Road Town Tortola British Virgin Islands VG1110 |
|
| April 16, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 9, 2024 |
April 9, 2024 2024 Research Investor Event Exhibit 99.1 April 9, 2024 2024 Research Investor Event 2 Our UK Labs 3 Agenda ▪ Business Update ▪ Our Research Strategy ▪ Our Platform ▪ Lead Candidates ▪ Forward Looking ▪ Closing Remarks ▪ Q&A 4 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not |
|
| April 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 9, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| March 15, 2024 |
ADC THERAPEUTICS SA 1,260,863 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-267295 PROSPECTUS ADC THERAPEUTICS SA 1,260,863 Common Shares Pursuant to this prospectus, the selling shareholders may offer common shares from time to time if and to the extent as they may determine as described in the section entitled “Plan of Distribution” at prevailing market prices, at prices different than prevailing market prices or at |
|
| March 15, 2024 |
ADC THERAPEUTICS SA 4,412,840 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-267293 PROSPECTUS ADC THERAPEUTICS SA 4,412,840 Common Shares Pursuant to this prospectus, the selling shareholders may offer common shares from time to time if and to the extent as they may determine as described in the section entitled “Plan of Distribution” at prevailing market prices, at prices different than prevailing market prices or at |
|
| March 13, 2024 |
Employment Letter Agreement with Ron Squarer #22010118v16 March 18, 2020 Ron Squarer Boulder, Colorado Dear Ron, Exhibit 10.23 It is with great pleasure that we provide you with this offer of employment with ADC Therapeutics SA (the “Company”) and nomination to the Board of Directors of the Company as the “Chairman of the Board.” The entire Board of Directors is supportive and excited that you will be joining us, so we write now to memoriali |
|
| March 13, 2024 |
Employment Transition Letter with Ron Squarer Exhibit 10.24 /!DC THERAPEUTICS October 10, 2022 Ron Squarer Boulder, Colorado Dear Ron, Reference is made to that certain letter from ADC Therapeutics SA (the "Company") to you dated as of March 18, 2020 (the "Employment Letter"). Pursuant to the Employment Letter, you serve both as an employee and as Chairman of the Board of Directors of the Company ("Chairman of the Board"). The Company desires |
|
| March 13, 2024 |
Form of Letter Agreement for Non-Employee Directors Exhibit 10.28 [DATE] [NAME] [ADDRESS] Dear [XYZ], Further to our recent discussions, we are very pleased to confirm the following terms and conditions for your role on the board of directors (Board of Directors) of ADC Therapeutics SA (the Company): Services Effective [INSERT DATE] you will be appointed initially as an observer to our Board of Directors and attend all meetings as if you were a dir |
|
| March 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables POS AM (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| March 13, 2024 |
Retention Bonus Letter Agreement with Jose Carmona December 12, 2023 Exhibit 10.21 Jose (Pepe) Carmona 721 Thomas Road Philadelphia, PA 19118 Dear Pepe: ADC Therapeutics SA (the “Company”) is pleased to offer you this Retention Bonus Letter Agreement. The Company values your continued contributions to its business and wishes to incentivize you to remain employed by the Company. The Company will pay you a one-time cash bonus equal to $360,000.00 (t |
|
| March 13, 2024 |
Executive Employment Agreement with Ameet Mallik 1 Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT This executive employment agreement (this “Agreement”) is made and entered into by and between the following parties (hereinafter, the “Parties”): Ameet Mallik (the “Executive”) on the one hand and ADC Therapeutics America, Inc., on the other hand (the “Company”), to be effective on May 6, 2022 (the “Effective Date”). WHEREAS, the Company desires to e |
|
| March 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables POS AM (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| March 13, 2024 |
Amendment to Executive Employment Agreement with Ameet Mallik ADC Therapeutics America, Inc. 430 Mountain Ave Suite 404 Murray Hill, NJ 07974 Exhibit 10.18 December 20, 2023 Ameet Mallik 84 Garfield Avenue Madison, NJ 07940 Re: Amendment to Executive Employment Agreement with ADC Therapeutics America, Inc. effective as of May 6, 2022 ("Executive Employment Agreement") Dear Ameet, As discussed, we would like to confirm that your Executive Employment Agreement |
|
| March 13, 2024 |
Employment Transition Letter with Michael Forer THERAPEUTICS Innovating Science. Inspiring Hope. ADC Therapeutics EXHIBIT 10.26 Biopole Route de la Corniche 38 1066 Epalinges, Switzerland April 20, 2023 Mr. Michael Forer Route des Pleiades 24A 1807 Blonay Re: Your employment with ADCT Dear Michael: Reference is made to your Employment Agreement with ADC Therapeutics SA (the "Company") effective as of October 1, 2015 (the "Employment Agreement") |
|
| March 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| March 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables POS AM (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024. As filed with the Securities and Exchange Commission on March 13, 2024. Registration No. 333-270570 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form F-3 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other |
|
| March 13, 2024 |
Employment Agreement with Jose Carmona 1 Exhibit 10.20 EXECUTIVE EMPLOYMENT AGREEMENT This executive employment agreement (this “Agreement”) is made and entered into by and between the following parties (hereinafter, the “Parties”): Jose (Pepe) Carmona (the “Executive”) on the one hand and ADC Therapeutics America, Inc., on the other hand (the “Company”), to be effective on December 19, 2022 (the “Effective Date”). WHEREAS, the Company |
|
| March 13, 2024 |
Clawback Policy Exhibit 97.1 Effective December 1, 2023 ADC Therapeutics Clawback Policy 1 Clawback Policy Table of Contents 1. Definitions 4 2. Recoupment of Erroneously Awarded Compensation 5 3. Administration 6 4. Amendment/Termination 7 5. Interpretation 7 6. Other Compensation Clawback/Recoupment Rights 7 7. Exempt Compensation 7 8. Miscellaneous 7 9. Document History 8 2 Clawback Policy This |
|
| March 13, 2024 |
Form of award agreement under the 2019 Equity Incentive Plan Exhibit 10.12.1 ADC THERAPEUTICS SA 2019 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION AWARD ADC Therapeutics SA (the “Company”) has granted the Participant, effective as of the Grant Date (as set forth below), a stock option to purchase Shares (the “Award”) under the ADC Therapeutics SA 2019 Equity Incentive Plan (as amended from time to time, the “Plan”). The Award is subject to the terms and con |
|
| March 13, 2024 |
Employment Transition Letter with Christopher Martin Head Office Biopôle Route de la Corniche 3B 1066 Epalinges, Switzerland Translation & Innovation Hub Building Imperial College White City Campus 84 Wood Lane London, W12 0BZ, UK Clinical, Commercial and US Operations 430 Mountain Avenue Suite 404 New Providence, NJ 07974, USA Chemistry Manufacturing and Control 1510 Fashion Island Boulevard Suite 205 San Mateo, CA 94404, USA ADC Therapeutics Exhibit 10. |
|
| March 13, 2024 |
Executive Employment Agreement with Mohamed Zaki Exhibit 10.22 Execution Version AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This amended and restated executive employment agreement (this “Agreement”) is made and entered into by and between the following parties (hereinafter, the “Parties”): Mohamed H. Zaki (the “Executive”) on the one hand and ADC Therapeutics America, Inc., on the other hand (the “Company”), to be effective on December |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024. As filed with the Securities and Exchange Commission on March 13, 2024. Registration No. 333-267295 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form F-3 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other |
|
| March 13, 2024 |
Exhibit 99.1 ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for |
|
| March 13, 2024 |
Retention Bonus Letter Agreement with Ameet Mallik December 12, 2023 Exhibit 10.19 Ameet Mallik 84 Garfield Avenue Madison, NJ 07940 Dear Ameet: ADC Therapeutics SA (the “Company”) is pleased to offer you this Retention Bonus Letter Agreement. The Company values your continued contributions to its business and wishes to incentivize you to remain employed by the Company. The Company will pay you a one-time cash bonus equal to $576,800.00 (the “Rete |
|
| March 13, 2024 |
Limited Waiver and Consent to Loan Agreement and Guaranty US-DOCS\147369310.6 Execution Version LIMITED WAIVER AND CONSENT TO LOAN AGREEMENT AND GUARANTY THIS LIMITED WAIVER AND CONSENT TO LOAN AGREEMENT AND GUARANTY (this “Waiver”) is entered into effective as of January 16, 2024 (the “Effective Date”) among ADC THERAPEUTICS SA, a company formed under the laws of Switzerland (the “Borrower”), each of the Borrower’s Subsidiaries party hereto, the Lenders |
|
| March 13, 2024 |
Form of award agreement under the Conditional Share Capital Plan Exhibit 10.14.1 ADC THERAPEUTICS SA CONDITIONAL SHARE CAPITAL PLAN NOTICE OF STOCK OPTION AWARD – GRANT LETTER ADC Therapeutics SA (the “Company”) has granted the Participant, effective as of the Grant Date (as set forth below), a stock option to purchase Shares (the “Award”) under the ADC Therapeutics SA Conditional Share Capital Plan (as amended from time to time, the “Plan”). The Award is subje |
|
| March 13, 2024 |
Consulting Agreement with Christopher Martin Head Office Biopôle Route de la Corniche 3B 1066 Epalinges, Switzerland Translation & Innovation Hub Building Imperial College White City Campus 84 Wood Lane London, W12 0BZ, UK Clinical, Commercial and US Operations 430 Mountain Avenue Suite 404 New Providence, NJ 07974, USA Chemistry Manufacturing and Control 1510 Fashion Island Boulevard Suite 205 San Mateo, CA 94404, USA ADC Therapeutics Exhibit 10. |
|
| March 13, 2024 |
4Q 2023 Earnings Call March 13, 2024 Exhibit 99.2 2 Forward‐Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the pre |
|
| March 13, 2024 |
EXHIBIT 4.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION The Company We are a Swiss stock corporation (société anonyme) organized under the laws of Switzerland. We were incorporated as a Swiss limited liability company (société à responsabilité limitée) on June 6, 2011 with our registered office and domicile in Epalinges, Canton of Vaud, Switzerland. We converted to a Swiss stock corpo |
|
| March 13, 2024 |
Employment Agreement with Michael Forer Execution Version Exhibit 10.25 Employment Agreement by and between ADC Therapeutics SA Bio pole, route de la Corniche 3 B, 1066 Epalinges, Switzerland (hereinafter the Company) and Michael Ferer Route des Pleiades 24A, 1807, Blonay, Switzerland (hereinafter the Employee) (together the Parties) Employment Agreement by and between ADC Therapeutics SA and Michael Forer 1. Introductory Provisions Aft |
|
| March 13, 2024 |
Consulting Agreement with Victor Sandor Page 1 of 9 Exhibit 10.30 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of October 1, 2022, 2022 (the “Effective Date”), between ADC THERAPEUTICS AMERICA, INC., with offices at 430 Mountain Avenue, Suite #404, New Providence, NJ 07974, USA (“ADCT”), and Dr. Victor Sandor, with personal address at 20 Wellington Lane, Belmont, MA. (“CONSULTANT”). ADCT a |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024. As filed with the Securities and Exchange Commission on March 13, 2024. Registration No. 333-267293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form F-3 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other |
|
| March 5, 2024 |
ADC Therapeutics Business Overview Cowen Conference March 5, 2024 Exhibit 99.1 ADC Therapeutics Business Overview Cowen Conference March 5, 2024 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promi |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 5, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Numb |
|
| February 29, 2024 |
Exhibit 10.1 ADC Therapeutics SA Annual Bonus Plan Effective: February 2024 1 Rationale and Objective ADC Therapeutics SA (“ADCT”) has created this Annual Bonus Plan (“Plan”) to reward employees for their contributions to the success of the Company. The Plan is an incentive form of cash compensation designed to better align employees’ interests with those of the Company and its stockholders. The C |
|
| February 14, 2024 |
ADCT / ADC Therapeutics SA / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ADC Therapeutics SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2024 |
EX-99.1 2 tm245846d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ADC The |
|
| February 13, 2024 |
ADCT / ADC Therapeutics SA / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d747565dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADC THERAPEUTICS SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 12, 2024 |
ADCT / ADC Therapeutics SA / ASTRAZENECA PLC - SC 13G/A Passive Investment SC 13G/A 1 tm245762d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title of Class of Securities) H0036K147 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Numbe |
|
| January 24, 2024 |
Letter Agreement, dated January 18, 2024, between ADC Therapeutics SA and Redmile LLC Exhibit 10.1 Agreement of 18 January 2024 between ADC Therapeutics SA Biopôle Route de la Corniche 3 B 1066 Epalinges Switzerland [email protected] “Company” and Redmile Group, LLC One Letterman Drive, Suite D3-300 San Francisco, CA 94129 United States [email protected] “Redmile” Company and Redmile each a “Party” collectively the “Parties” regarding the pre-emptive and advance s |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 16, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Numbe |
|
| January 19, 2024 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO LOAN AGREEMENT AND GUARANTY THIS FIRST AMENDMENT TO LOAN AGREEMENT AND GUARANTY (this “Amendment”) is entered into effective as of January 16, 2024 (the “First Amendment Effective Date”) among ADC THERAPEUTICS SA, a company formed under the laws of Switzerland (the “Borrower”), each of the Borrower’s Subsidiaries party hereto, the Lenders party her |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 4, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 4, 2024 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number |
|
| January 4, 2024 |
Exhibit 99.1 ADC Therapeutics Provides Business Updates ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort with no DLT and with early signs of efficacy ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antit |
|
| January 4, 2024 |
Business Update January 4, 2024 Exhibit 99.2 Business Update January 4, 2024 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presen |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| December 18, 2023 |
Filing fee table (filed herewith) Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount |
|
| December 18, 2023 |
As filed with the Securities and Exchange Commission on December 18, 2023 As filed with the Securities and Exchange Commission on December 18, 2023 Registration No. |
|
| December 4, 2023 |
Filing fee table (filed herewith) Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount |
|
| December 4, 2023 |
Exhibit 99.2 ADC THERAPEUTICS SA INDUCEMENT PLAN Section 1. Purpose. The purpose of the ADC Therapeutics Inducement Plan (the “Plan”) is to motivate and reward new employees of ADC Therapeutics SA (the “Company”) and its Subsidiaries to perform at the highest level and to further the best interests of the Company and its shareholders. Capitalized terms not otherwise defined herein are defined in |
|
| December 4, 2023 |
Conditional Share Capital Plan Exhibit 99.1 ADC THERAPEUTICS SA CONDITIONAL SHARE CAPITAL PLAN Section 1. Purpose. The purpose of the ADC Therapeutics Conditional Share Capital Plan (the “Plan”) is to motivate and reward employees, directors, consultants, contractors and other persons providing services to ADC Therapeutics SA (the “Company”) and its Subsidiaries to perform at the highest level and to further the best interests |
|
| December 4, 2023 |
As filed with the Securities and Exchange Commission on December 4, 2023 As filed with the Securities and Exchange Commission on December 4, 2023 Registration No. |
|
| November 7, 2023 |
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.3 ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates 3Q 2023 ZYNLONTA®1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses decreased 23%2 year-over-year due to portfolio prioritization and operational efficiencies; Expected c |
|
| November 7, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| November 7, 2023 |
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards Exhibit 99.1 ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards Lausanne, Switzerland, November 7, 2023 – ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of |
|
| November 7, 2023 |
Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended September 30, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidate |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address |
|
| September 11, 2023 |
Morgan Stanley Global Healthcare Conference September 11, 2023 Exhibit 99.1 Morgan Stanley Global Healthcare Conference September 11, 2023 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| August 8, 2023 |
Exhibit 99.3 ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update 2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio prioritization and organizational efficiencies Pipeline advancing with initial data readouts fr |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of p |
|
| August 8, 2023 |
Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and six months ended June 30, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidated Inte |
|
| August 8, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of pr |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of pr |
|
| June 14, 2023 |
Exhibit 99.1 Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorpor |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of pr |
|
| May 9, 2023 |
Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three months ended March 31, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidated Interim Sta |
|
| May 9, 2023 |
Exhibit 99.3 ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update 1Q 2023 ZYNLONTA®1 net sales increased 15% and operating expenses decreased 19% year-over-year2; FY 2023 guidance reaffirmed for ZYNLONTA double-digit net sales growth and reduction in operating expenses as compared to FY 2022 Implementing new go-to-market model to help drive growth |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of prin |
|
| May 9, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of pri |
|
| May 5, 2023 |
Exhibit 99.4 1 U P X 1. 2. F o r A gain s t A bs t ain F o r A gain s t A bs t ain F o r A gain s t A bs t ain F o r 4.c. 4.h. 6. A gain s t A bs t ain 3. 4 .a. 4 . b. 4.d. 4.i. 7. 4.e . 5 . a . 8.a. 4 . f . 5 . b . 8. b . 4.g. 5.c. 8.c. 9. 1 0 . F o r A gain s t A bs t ain Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. |
|
| May 5, 2023 |
Exhibit 99.2 Smartphone users Point your camera here and vote without entering a control number V1.1 Your Vote Counts! ADC THERAPEUTICS SA 2023 Annual General Meeting Vote by June 8, 2023 at 11:59 p.m. EDT / June 9, 2023 at 5:59 a.m. CEST For complete information and to vote, visit www.ProxyVote.com Control # V17582 - P92844 You invested in ADC THERAPEUTICS SA and it’s time to vote! You have the r |
|
| May 5, 2023 |
To the shareholders of ADC Therapeutics SA Invitation to the Annual General Meeting Exhibit 99.1 To the shareholders of ADC Therapeutics SA Invitation to the Annual General Meeting Date and Time: Wednesday, June 14, 2023, at 4:00 a.m. EDT / 10:00 a.m. CEST Location: Headquarters of ADC Therapeutics SA, Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland Dear Shareholders, It is my pleasure to update you on ADC Therapeutics’ achievements in 2022 and our strategic objecti |
|
| May 5, 2023 |
Exhibit 99.3 1 U P X 1. 2. F o r A gain s t A bs t ain F o r A gain s t A bs t ain F o r A gain s t A bs t ain F o r 4.c. 4.h. 6. A gain s t A bs t ain 3. 4 .a. 4 . b. 4.d. 4.i. 7. 4.e . 5 . a . 8.a. 4 . f . 5 . b . 8. b . 4.g. 5.c. 8.c. 9. 1 0 . F o r A gain s t A bs t ain a b s t ain Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the design |
|
| April 28, 2023 |
ADCT / Adc Therapeutics SA / AUVEN THERAPEUTICS HOLDINGS LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title and Class of Securities) H0036K147 (CUSIP Number) Stephen Evans-Freke Auven Therapeutics Holdings L.P. 171 Main Street Road Town Tortola British Virgin Islan |
|
| April 28, 2023 |
EX-99.1 Exhibit 99.1 This SHARE TRANSFER AGREEMENT, dated as of April 27, 2023 (this “Agreement”), is entered into by and between A.T. HOLDINGS II SÀRL, a limited liability company duly incorporated on February 25, 2010 and existing in accordance with the laws of Switzerland, registered at the Commercial Register of the Canton of Vaud under number CHE-115.457.113 (the “Borrower”), and each lender |
|
| April 17, 2023 |
JOINT FILING AGREEMENT April 14, 2023 EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT April 14, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includ |
|
| April 17, 2023 |
ADCT / Adc Therapeutics SA / Prosight Management, LP - SC 13G Passive Investment SC 13G 1 d501227dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADC THERAPEUTICS SA (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) April 6, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) ADC Therapeutics SA (Name of Subject Company (Issuer)) ADC Therapeutics SA, as Issuer and Offeror (Name of Filing Persons (Identifying status as offeror, issuer, or other person)) Options to purchase c |
|
| March 30, 2023 |
= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) ADC Therapeutics SA (Name of Subject Company (Issuer)) ADC Therapeutics SA, as Issuer and Offeror (Name of Filing Persons (Identifying status as offeror, issuer, or other person)) Options to purchase |
|
| March 30, 2023 |
Form of Reminder Email for Options Exchange Exhibit (a)(1)(o) ADC Therapeutics Offer to Exchange Eligible Options for New Options Dear Colleague, We want to remind you that the ADC Therapeutics (“ADCT,” “we,” “us” or “our”) Offer to Exchange Eligible Options for New Options (the “Exchange Offer”) will expire at 4:00 PM Eastern Time on Monday, April 3rd, 2023 (the “Expiration Time”). |
|
| March 29, 2023 |
Exhibit (a)(1)(N) Form of Reminder Email to Eligible Participants With No Election Regarding the Expiration of the Exchange Offer From: AwardTraq Exchange Subject: Exchange Offer Reminder – ACTION REQUESTED Hello [First Name], If you are receiving this notice, this means your elections have not been confirmed in the system. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ADC Therapeutics SA (Name of Subject Company (Issuer)) ADC Therapeutics SA, as Issuer and Offeror (Name of Filing Persons (Identifying status as offeror, issuer, or other person)) Options to purchase c |
|
| March 21, 2023 |
March 21, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ADC Therapeutics SA (Name of Subject Company (Issuer)) ADC Therapeutics SA, as Issuer and Offeror (Name of Filing Persons (Identifying status as offeror, issuer, or other person)) Options to purchase c |
|
| March 16, 2023 |
+1 212 450 4000 davispolk.com Davis Polk & Wardwell llp 450 Lexington Avenue New York, NY 10017 March 16, 2023 Re: ADC Therapeutics SA Schedule TO-I filed March 6, 2023 File No. 005-91517 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christina Chalk Blake Grady Dear Ms. Chalk and Mr. Grady: On behalf of our client, ADC |
|
| March 15, 2023 |
Consent of PricewaterhouseCoopers SA, independent registered public accounting firm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. |
|
| March 15, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ameet Mallik, certify that: 1.I have reviewed this annual report on Form 20-F of ADC Therapeutics SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| March 15, 2023 |
Exhibit 4.9 Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA has determined that the information (i) is not material and (ii) is customarily and actually treated by ADC Therapeutics as private or confidential. LICENSE AGREEMENT BETWEEN ADC Therapeutics SA AND Swedish Orphan Biovitrum AB (publ) Certain confidential information |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 15, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with ADC Therapeutics SA’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange A |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Articles of Association of ADC Therapeutics SA Exhibit 4.1 Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorpora |
|
| March 15, 2023 |
Exhibit 4.2 ADC THERAPEUTICS SA INDENTURE Dated as of [] [], as Trustee TABLE OF CONTENTS Article 1 Definition and Incorporation by Reference Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 Article 2 The Securities Section 2.01. Issuable in Series 5 Section 2.02. Establishment of T |
|
| March 15, 2023 |
Exhibit 99.1 ADC THERAPEUTICS SA 2019 EQUITY INCENTIVE PLAN (as amended and restated effective February 8, 2023) Section 1. Purpose. The purpose of the ADC Therapeutics SA 2019 Equity Incentive Plan (the “Plan”) is to motivate and reward employees, directors, consultants and advisors of ADC Therapeutics SA (the “Company”) and its Subsidiaries to perform at the highest level and to further the best |
|
| March 15, 2023 |
ADC Therapeutics SA 2022 Annual Report Table of Contents Exhibit 99.1 ADC Therapeutics SA 2022 Annual Report Annual Report 1 Table of Contents Table of Contents Letter to Shareholders 3 Business Update 5 Financial Review 59 Corporate Governance 76 Report from the Auditor on the Consolidated IFRS Financial Statements 91 Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 99 Report from the Auditor on the Statutor |
|
| March 15, 2023 |
Report on Form 6-K filed with the SEC on March 15, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of p |
|
| March 15, 2023 |
Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) 332012|9899338v5 Articles of Association of ADC Therapeutics SA Section 1 Name, Registered Office, Purpose and Duration of the Company Section 1 Raison sociale, siège, but de la société, durée Article 1 Article 1 Name, Place of Incorporation Under the name ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) (the Company) shall exist a corporation with its registered office in Epalinges, canton of Vaud. |
|
| March 15, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with ADC Therapeutics SA’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange A |
|
| March 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables F-3 (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| March 15, 2023 |
Filing fee table (filed herewith) Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023. As filed with the Securities and Exchange Commission on March 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R |
|
| March 15, 2023 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jose Carmona, certify that: 1.I have reviewed this annual report on Form 20-F of ADC Therapeutics SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| March 15, 2023 |
EXHIBIT 2.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION The Company We are a Swiss stock corporation (société anonyme) organized under the laws of Switzerland. We were incorporated as a Swiss limited liability company (société à responsabilité limitée) on June 6, 2011 with our registered office and domicile in Epalinges, Canton of Vaud, Switzerland. We converted to a Swiss stock corpo |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of p |
|
| March 6, 2023 |
Form of Email Confirming Receipt of Election Form Exhibit (a)(1)(E) Form of Email Confirming Receipt of Election Form From: AwardTraq Exchange Subject: Your Option Exchange Elections Hello [First Name], Thank you for submitting your elections through the AwardTraq Option Exchange Portal. |
|
| March 6, 2023 |
Form of Option Exchange Election Form on the Option Exchange Portal Exhibit (a)(1)(D) Option Exchange Election Form on the Exchange Portal Below is an example of what eligible option holders will be able to view when they go to the option exchange portal. The information will be customized and contain outstanding and eligible stock options that belong to each individual: |
|
| March 6, 2023 |
Offer to Exchange Eligible Options for New Options, dated March 6, 2023 Exhibit (a)(1)(A) ADC THERAPEUTICS SA Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS March 6, 2023 SUMMARY TERM SHEET — OVERVIEW Offer to Exchange Eligible Options for New Options This offer and withdrawal rights will expire at 4:00 p. |
|
| March 6, 2023 |
Exhibit FILING FEES CALCULATION OF FILING FEE TABLES Table 1 – Transaction Valuation Transaction Valuation(1) Fee Rate Amount of Filing Fee(2) Fees to Be Paid $6,108,543 0. |
|
| March 6, 2023 |
Presentation, dated March 6, 2023 Exhibit (1)(a)(L) March 2023 Stock Options Equity Exchange 2 Agenda ▪ What is a stock option exchange? ▪ Why offer a stock option exchange? ▪ Eligibility ▪ How a stock option exchange works ▪ Exchange ratio ▪ New options terms ▪ Example of participating vs. |
|
| March 6, 2023 |
Form of Email to Eligible Participants Confirming Acceptance of Eligible Options Exhibit (a)(1)(G) Form of Email to Eligible Participants Confirming Acceptance of Eligible Options From: AwardTraq Exchange Subject: Confirmation of Acceptance of Eligible Options Hello [First Name], Thank you for your submission of the Election Form pursuant to the Offer to Exchange Eligible Options for New Options, dated March 6, 2023 (the “Offer to Exchange”). |
|
| March 6, 2023 |
Form of Email Providing the Link to the Exchange Offer Election Form on the Option Exchange Portal Exhibit (a)(1)(C) Providing the Link to the Exchange Offer Election Form on the Option Exchange Portal From: AwardTraq Exchange Subject: Welcome to the Option Exchange Portal Hello [First Name], ADC Therapeutics has created a user account for you in the AwardTraq Option Exchange Portal. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ADC Therapeutics SA (Name of Subject Company (Issuer)) ADC Therapeutics SA, as Issuer and Offeror (Name of Filing Persons (Identifying status as offeror, issuer, or other person)) Options to purchase common shares, par |
|
| March 6, 2023 |
Form of Reminder Email to Eligible Participants Regarding the Expiration of the Exchange Offer Exhibit (a)(1)(F) Form of Reminder Email to Eligible Participants Regarding the Expiration of the Exchange Offer From: AwardTraq Exchange Subject: Exchange Offer Reminder Hello [First Name], We are sending this email to remind you that the previously announced Offer to Exchange Eligible Options for New Options (the “Exchange Offer”) is still open and you are able to make an election until 4pm ET on April 3, 2023 unless extended by ADC Therapeutics in accordance with the Offer to Exchange. |
|
| March 6, 2023 |
Form of New Option Agreement (Partially Vested Options) Exhibit (a)(1)(J) Version: Partially Vested ADC THERAPEUTICS SA 2019 EQUITY INCENTIVE PLAN NOTICE OF NEW OPTION AWARD – GRANT LETTER In connection with the offer to exchange certain options for new options pursuant to the Offer to Exchange Eligible Options for New Options Summary Term Sheet dated March 6, 2023 (the “Summary Term Sheet”, and such offer, the “Exchange Offer”), ADC Therapeutics SA (the “Company”) has granted the Participant, effective as of the Grant Date (as set forth below), a new stock option to purchase Shares (the “Award”) under the ADC Therapeutics SA 2019 Equity Incentive Plan (as amended from time to time, the “Plan”). |
|
| March 6, 2023 |
Form of Announcement to Eligible Holders Exhibit (a)(1)(B) Form of Announcement Email to Eligible Holders ADC Therapeutics Offer to Exchange Eligible Options for New Options Dear Colleague, I’d like to begin by thanking you for everything you do to help us execute on our strategic goals. |
|
| March 6, 2023 |
Form of New Option Agreement (Unvested Options) Exhibit (a)(1)(I) Version: Unvested ADC THERAPEUTICS SA 2019 EQUITY INCENTIVE PLAN NOTICE OF NEW OPTION AWARD – GRANT LETTER In connection with the offer to exchange certain options for new options pursuant to the Offer to Exchange Eligible Options for New Options Summary Term Sheet dated March 6, 2023 (the “Summary Term Sheet”, and such offer, the “Exchange Offer”), ADC Therapeutics SA (the “Company”) has granted the Participant, effective as of the Grant Date (as set forth below), a new stock option to purchase Shares (the “Award”) under the ADC Therapeutics SA 2019 Equity Incentive Plan (as amended from time to time, the “Plan”). |
|
| March 6, 2023 |
Form of Email Notice Regarding Rejection of Options for Exchange Exhibit (a)(1)(H) Form of Email Notice Regarding Rejection of Options for Exchange From: AwardTraq Exchange Subject: Notice of Rejection of Eligible Options Hello [First Name], Thank you for your submission of the Election Form pursuant to the Offer to Exchange Eligible Options for New Options, dated March 6, 2023 (the “Offer to Exchange”). |
|
| March 6, 2023 |
Accompanying Script for Presentation, dated March 6, 2023 Exhibit (a)(1)(M) Cover/Title Slide Slide 1: AMEET: Hello and welcome to our presentation on ADCT’s Stock Options Exchange Offering – which opens today I'm Ameet Mallik and I am joined by Kim Pope, our chief people officer, and Marina Koval, people operations manager. |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ADC Therapeutics SA (Name of Subject Company (Issuer)) ADC Therapeutics SA, as Issuer and Offeror (Name of Filing Persons (Identifying status as offeror, issuer, or other person)) Options to purchase common shares, par |
|
| March 3, 2023 |
Exhibit (a)(1)(A) Town Hall March 3, 2023 2 Recognizing Our People ▪ Stock option exchange offer ▪ Rolls out Monday, March 6th, ends on Monday, April 3 rd ▪ Webcast on Monday at 10 a.m. Eastern, recorded and posted on our intranet, Our ADCT ▪ Emails and instructions will be sent to you from Equity Methods AwardTraq CONFIDENTIAL – For ADCT Internal Use Only |
|
| February 28, 2023 |
6-K 1 dp1897806k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Ep |
|
| February 10, 2023 |
ADCT / Adc Telecommunications Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ADC Therapeutics SA. (Name of Issuer) Common Shares (Title of Class of Securities) H0036K147 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2023 |
EX-99.1 2 tm236041d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ADC The |
|
| February 6, 2023 |
EX-99.1 2 d460190dex991.htm EX-99.1 Exhibit 99.1 12,000,000 Shares ADC THERAPEUTICS SA COMMON SHARES, NOMINAL VALUE CHF 0.08 PER SHARE UNDERWRITING AGREEMENT February 2, 2023 February 2, 2023 Jefferies LLC As Representative of the several Underwriters named in Schedule II hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: The shareholder named in Schedule I |
|
| February 6, 2023 |
EX-4.1 3 dp188380ex0401.htm EXHIBIT 4.1 Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”), dated as of February 6, 2023, has been entered into by and among ADC Therapeutics SA, a Swiss stock corporation (société anonyme) (the “Company”), and Oaktree Fund Administration LLC, a Delaware limited liability company, OCM Strategic Credit Investments S.à r.l. |
|
| February 6, 2023 |
EXHIBIT 1.1 12,000,000 Shares ADC Therapeutics SA Common SHares, nominal Value CHF 0.08 PER SHARE UNDERWRITING AGREEMENT February 2, 2023 February 2, 2023 Jefferies LLC As Representative of the several Underwriters named in Schedule II hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: The shareholder named in Schedule I hereto (the “Selling Shareholder”) p |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| February 6, 2023 |
ADC Therapeutics SA Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland EXHIBIT 99.1 ADC Therapeutics SA Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland February 2, 2023 A.T. Holdings II Sàrl Ritter House P.O. Box 4041 Wickhams Cay II Road Town, Tortola, BVI VG1110 This letter agreement (the “Letter Agreement”) is entered into between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Switzerland, and organized under the laws of Switzerland (the |
|
| February 6, 2023 |
ADC Therapeutics SA Route de la Corniche 3B 1066 Epalinges EX-99.2 Exhibit 99.2 ADC Therapeutics SA Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland February 2, 2023 A.T. Holdings II Sàrl Ritter House P.O. Box 4041 Wickhams Cay II Road Town, Tortola, BVI VG1110 This letter agreement (the “Letter Agreement”) is entered into between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Switzerland, and organized under the laws of Switzerl |
|
| February 6, 2023 |
[Signature Page to Lock-Up Letter] EX-99.3 Exhibit 99.3 February 2, 2023 Jefferies LLC c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned understands that Jefferies LLC, as representative (the “Representative”) of the several Underwriters, proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with ADC Therapeutics SA, a société anonyme organized under the la |
|
| February 6, 2023 |
ADCT / Adc Telecommunications Inc / AUVEN THERAPEUTICS HOLDINGS LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title and Class of Securities) H0036K147 (CUSIP Number) Stephen Evans-Freke Auven Therapeutics Holdings L.P. 171 Main Street Road Town Tortola British Virgin Islan |
|
| February 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424B7 (Form Type) ADC Therapeutics SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Shares Rule 457(r) 12,000,000 $5. |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| February 2, 2023 |
ADC THERAPEUTICS SA 12,000,000 Common Shares Filed pursuant to Rule 424(b)(7) Registration No. 333-256807 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JUNE 4, 2021) ADC THERAPEUTICS SA 12,000,000 Common Shares The selling shareholder of ADC Therapeutics SA named in this prospectus supplement is selling 12,000,000 of our common shares. We are not selling any common shares included in this prospectus supplement and will not receive any of t |
|
| February 2, 2023 |
Filed pursuant to Rule 433 Issuer Free Writing Prospectus, dated February 2, 2023 Registration No. |
|
| February 2, 2023 |
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder Filed pursuant to Rule 433 Issuer Free Writing Prospectus, dated February 2, 2023 Registration No. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| January 9, 2023 |
Ameet Mallik, CEO January 11, 2023 J.P. Morgan Healthcare Conference EX-99.1 2 dp186760ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Ameet Mallik, CEO January 11, 2023 J.P. Morgan Healthcare Conference 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or sh |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| January 4, 2023 |
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer EX-99.1 2 dp186634ex9901.htm EXHIBIT 99.1 ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer LAUSANNE, Switzerland, January 3, 2023 – ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company’s executive leadership team. Dr. Zaki succeeds Joseph Cam |
|
| January 4, 2023 |
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference LAUSANNE, Switzerland, January 4, 2023 – ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT. A live webcast of the presenta |
|
| December 23, 2022 |
ADCT / Adc Telecommunications Inc / AUVEN THERAPEUTICS HOLDINGS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title and Class of Securities) H0036K147 (CUSIP Number) Stephen Evans-Freke Auven Therapeutics Holdings L.P. 171 Main Street Road Town Tortola British Virgin Islands VG1110 |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| December 21, 2022 |
Exhibit 99.1 ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Approval triggers $50 million milestone payment to ADC Therapeutics LAUSANNE, Switzerland, December 21, 2022 – ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Europea |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| December 19, 2022 |
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer EXHIBIT 99.1 ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer LAUSANNE, Switzerland, December 19, 2022 – ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company’s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities. |
|
| December 9, 2022 |
ADCT / Adc Telecommunications Inc / AUVEN THERAPEUTICS HOLDINGS LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title and Class of Securities) H0036K147 (CUSIP Number) Stephen Evans-Freke Auven Therapeutics Holdings L.P. 171 Main Street Road Town Tortola British Virgin Islands VG1110 |
|
| December 8, 2022 |
ADCT / Adc Telecommunications Inc / AUVEN THERAPEUTICS HOLDINGS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ADC Therapeutics SA (Name of Issuer) Common Shares, par value CHF 0.08 per share (Title and Class of Securities) H0036K147 (CUSIP Number) Stephen Evans-Freke Auven Therapeutics Holdings L.P. 171 Main Street Road Town Tortola British Virgin Islands VG1110 |
|
| November 8, 2022 |
Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended September 30, 2022. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidate |
|
| November 8, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| November 8, 2022 |
Exhibit 99.3 ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates ZYNLONTA? (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs.2Q 2022) Cash runway expected into early 2025 Company to host conference call today at 8:30 a.m. EST Lausanne, Switzerland, November 8, 2022 ? ADC Therapeutics SA (NYSE: ADCT) today reported |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biop?le Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| November 7, 2022 |
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference Exhibit 99.1 ADC Therapeutics to Participate in the Jefferies London Healthcare Conference LAUSANNE, Switzerland, November 7, 2022 ? ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT. A live webcast of the presentation will be avail |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biop?le Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| November 3, 2022 |
Exhibit 99.1 ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting Multiple presentations will highlight the clinical utility of ZYNLONTA? (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma Lausanne, Switzerland, November 3, 2022 ? ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody d |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biop?le Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| November 2, 2022 |
Exhibit 99.1 IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA? in Patients with Relapsed or Refractory B Cell Non-Hodgkin?s Lymphoma ? Companies to Leverage Lead Product Candidate from IGM?s Proprietary IgM Antibody Platform with ZYNLONTA? for Novel Combination Therapy in Relapsed/Refractory B Cell NHL ? ? |
|
| November 2, 2022 |
6-K 1 dp1837716k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Ep |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biop?le Route de la Corniche 3B 1066 Epalinges Switzerland (Address o |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of |
|
| October 31, 2022 |
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022 Exhibit 99.1 ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022 Lausanne, Switzerland, October 31, 2022 – ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates. To access the c |
|
| September 22, 2022 |
6-K 1 dp1808606k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 E |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biop?le Route de la Corniche 3B 1066 Epalinges Switzerland (Address |
|
| September 16, 2022 |
ADC THERAPEUTICS SA 4,412,840 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-267293 PROSPECTUS ADC THERAPEUTICS SA 4,412,840 Common Shares Pursuant to this prospectus, the selling shareholders may offer common shares from time to time if and to the extent as they may determine as described in the section entitled ?Plan of Distribution? at prevailing market prices, at prices different than prevailing market prices or at |
|
| September 16, 2022 |
ADC THERAPEUTICS SA 1,260,863 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-267295 PROSPECTUS ADC THERAPEUTICS SA 1,260,863 Common Shares Pursuant to this prospectus, the selling shareholders may offer common shares from time to time if and to the extent as they may determine as described in the section entitled ?Plan of Distribution? at prevailing market prices, at prices different than prevailing market prices or at |
|
| September 14, 2022 |
CORRESP 1 filename1.htm September 14, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ADC Therapeutics SA Registration Statement on Form F-3 Registration No. 333-267293 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of |
|
| September 14, 2022 |
September 14, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 7, 2022 |
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference Exhibit 99.1 ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference LAUSANNE, Switzerland, September 6, 2022 – ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET. A live webcast o |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biop?le Route de la Corniche 3B 1066 Epalinges Switzerland (Address |
|
| September 6, 2022 |
As filed with the Securities and Exchange Commission on September 6, 2022. As filed with the Securities and Exchange Commission on September 6, 2022. Registration No. 333-?????? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organizat |
|
| September 6, 2022 |
As filed with the Securities and Exchange Commission on September 6, 2022. As filed with the Securities and Exchange Commission on September 6, 2022. Registration No. 333-??? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADC THERAPEUTICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization |
